CORAL GABLES, FL / ACCESSWIRE / December 14, 2018 / Markets have been volatile this week after a number of political moves have shaken up investors. On Friday, however, healthcare and biotechnology stocks have seen more bullish moves that the broader markets.
In fact, according to numerous reports including one recently from Business Insider, healthcare is the only sector in the S&P 500 with double-digit gains this year. With its 11.1% gain this year, the sector is the only group in the S&P 500 to boast double-digit gains in 2018, outperforming other winners like utilities and consumer discretionary.
"Growth-oriented managers have to go somewhere when they sell their Tech holdings. Not many other sectors offer reliable growth," said Nicholas Colas, co-founder of DataTrek Research, in a note to clients on Thursday.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally. This is in line with the latest trend that's been growing within healthcare targeting new connected technology.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) announced this quarter that it will be planning on rolling out new initiatives. This includes entering the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019, as a part of its expansion plans.
Earlier this month, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) also recently announced that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy. The Company expects the acquisition to close in or about Q1-19. Additionally, the Company has engaged with healthcare technology providers and expects to provide further updates on its HealthVue app and other technology initiatives in the coming weeks.
Allscripts (MDRX) announced this week that it has signed a definitive agreement to sell its interests in Netsmart Technologies, Inc. Since then, shares have been on the rise.
According to the company, in March 2016, Allscripts contributed its homecare business to Netsmart, in exchange for the largest ownership stake in the company which has now become the largest technology company exclusively dedicated to behavioral health, human services and post-acute care. It is expected that this sale transaction will yield Allscripts net after-tax proceeds of approximately $525 million or approximately $3 per fully diluted share. Allscripts anticipates closing the sale by the end of the fourth quarter of 2018, after the satisfaction of customary closing conditions.
Shares of Allscripts jumped to highs of $10.35 during the morning trading session on Friday.
Following the uptrend in healthcare stocks, shares of Teladoc Health (TDOC) have been on the rise during Friday morning trading. The company's award-winning, integrated clinical solutions are inclusive of telehealth, expert medical services, AI and analytics, and licensable platform services.
Earlier this year, the company launched Best Doctors Specialty Pharmacy Services, a virtual care solution designed to tackle rising prescription drug costs using advanced analytics and an expert medical opinion.
According to the company, this analytics-driven virtual care solution helps employers and plan sponsors identify members with complex conditions such as Crohn's disease, psoriasis, lupus, or rheumatoid arthritis, and then engages an expert clinical team to carefully review the diagnosis and treatment plan to ensure the right course of action for each patient.
Alliqua BioMedical, Inc. (ALQA) saw its shares jump on Friday morning as well. The company saw one of its most active trading days since late November. Furthermore, Alliqua reached highs of $3.35 during the first hour of trading. The company has been awarded a government grant.
for the Phase 2 study of Brivoligide in patients undergoing mastectomy. The grant was announced via SEC filing, and comes from the National Institute on Drug Abuse. Though no press was released, investors have found this filing and the market has reacted favorably on Friday.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.